5 news items
Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic
COYA
20 Jun 24
for participation and stratification in clinical studies, and assess treatment response. In addition, Coya and HMRI will continue exploring the potential synergy
Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology
COYA
11 Jun 24
, "A Phase 1 Proof-of-Concept Study Evaluating Safety, Tolerability, and Biological Marker Responses with Combination Therapy
Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology
COYA
3 Jun 24
1 Proof-of-Concept Study Evaluating Safety, Tolerability, and Biological Marker Responses with Combination Therapy of CTLA4-Ig and Interleukin-2
EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases
BIIB
COYA
27 May 24
not be the most appropriate framework for neurodegenerative disorders and may be partly responsible for the lack of available and truly effective
Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer's Drug Discovery Foundation (ADDF)
COYA
20 May 24
system inflammatory response. Like Coya, the ADDF believes that combination therapies are the future of Alzheimer's and related dementia treatments
- Prev
- 1
- Next